Ajanta Pharma Q1 net up 12 percent at Rs 106 crore
New Delhi: Ajanta Pharma reported 11.60 percent rise in consolidated net profit at Rs 105.79 crore for the June quarter on account of robust sales in branded generic business.
The company had posted a net profit of Rs 94.79 crore in the year-ago period, Ajanta Pharma said in a BSE filing.
Consolidated income from operations stood at Rs 510.99 crore for the reported quarter. It was Rs 473.12 crore for the same period a year ago.
"We are pleased with our June quarter performance which is in line with our expectations. Branded generic business in India and Export markets posted healthy growths," MD Yogesh Agrawal said.
Despite challenging pricing environment in the US, the company has posted healthy growth for the quarter, he added.
"Going forward, branded generic business in India and Emerging Markets, and generic business in the US will be key focus markets for us," Agrawal said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd